Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris

PEMPULS trial

Leon F. Mentink, Maria W. Mackenzie, Gábor G. Tóth, Marianne Laseur, Frank P G Lambert, Nic J G M Veeger, Giuseppe Cianchini, Miloš D. Pavlović, Marcel F. Jonkman

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Objective: To determine the therapeutic effect of adjuvant dexamethasone pulse therapy when given in addition to conventional treatment of pemphigus vulgaris. Design: A randomized, placebo-controlled trial. Setting: International European, multicenter outpatient and inpatient study. Patients: Of the 20 enrolled patients, 11 were randomized to the dexamethasone pulse (DP) group and 9 to the placebo pulse (PP) group. Interventions: Oral dexamethasone in 300-mg pulses or PPs 3 days per month. During the intervention, the DP and PP groups received conventional treatment with prednisolone, 80 mg/d, which was tapered across 19 weeks, and azathioprine sodium, 3 mg/kg per day, until the end of the study. Monthly pulses were continued until prednisolone treatment was tapered to 0 mg. Main Outcome Measures: Number of patients in remission, time to and duration of remission, cumulative prednisolone dose, and occurrence of adverse events during 1 year of follow-up. Results: Eight of the 11 DP-treated patients and all 9 PP-treated patients achieved remission. Mean time to remission was 173 days with DP and 176 days with PP. The mean duration of remission within the first year was 151 days for DP and 141 days for PP. Mean cumulative prednisolone dose was 5300 mg for DP and 4882 mg for PP. Weight gain (>5% of baseline) occurred in 8 DP-treated patients compared with 1 PP-treated patient (P

Original languageEnglish
Pages (from-to)570-576
Number of pages7
JournalArchives of Dermatology
Volume142
Issue number5
DOIs
Publication statusPublished - May 2006

Fingerprint

Pemphigus
Dexamethasone
Randomized Controlled Trials
Placebos
Prednisolone
Therapeutics
Azathioprine
Therapeutic Uses
Weight Gain
Inpatients
Outpatients
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Dermatology

Cite this

Mentink, L. F., Mackenzie, M. W., Tóth, G. G., Laseur, M., Lambert, F. P. G., Veeger, N. J. G. M., ... Jonkman, M. F. (2006). Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Archives of Dermatology, 142(5), 570-576. https://doi.org/10.1001/archderm.142.5.570

Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris : PEMPULS trial. / Mentink, Leon F.; Mackenzie, Maria W.; Tóth, Gábor G.; Laseur, Marianne; Lambert, Frank P G; Veeger, Nic J G M; Cianchini, Giuseppe; Pavlović, Miloš D.; Jonkman, Marcel F.

In: Archives of Dermatology, Vol. 142, No. 5, 05.2006, p. 570-576.

Research output: Contribution to journalArticle

Mentink, LF, Mackenzie, MW, Tóth, GG, Laseur, M, Lambert, FPG, Veeger, NJGM, Cianchini, G, Pavlović, MD & Jonkman, MF 2006, 'Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial', Archives of Dermatology, vol. 142, no. 5, pp. 570-576. https://doi.org/10.1001/archderm.142.5.570
Mentink, Leon F. ; Mackenzie, Maria W. ; Tóth, Gábor G. ; Laseur, Marianne ; Lambert, Frank P G ; Veeger, Nic J G M ; Cianchini, Giuseppe ; Pavlović, Miloš D. ; Jonkman, Marcel F. / Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris : PEMPULS trial. In: Archives of Dermatology. 2006 ; Vol. 142, No. 5. pp. 570-576.
@article{7ddfb68f95144518a66d8d4ae62116e9,
title = "Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial",
abstract = "Objective: To determine the therapeutic effect of adjuvant dexamethasone pulse therapy when given in addition to conventional treatment of pemphigus vulgaris. Design: A randomized, placebo-controlled trial. Setting: International European, multicenter outpatient and inpatient study. Patients: Of the 20 enrolled patients, 11 were randomized to the dexamethasone pulse (DP) group and 9 to the placebo pulse (PP) group. Interventions: Oral dexamethasone in 300-mg pulses or PPs 3 days per month. During the intervention, the DP and PP groups received conventional treatment with prednisolone, 80 mg/d, which was tapered across 19 weeks, and azathioprine sodium, 3 mg/kg per day, until the end of the study. Monthly pulses were continued until prednisolone treatment was tapered to 0 mg. Main Outcome Measures: Number of patients in remission, time to and duration of remission, cumulative prednisolone dose, and occurrence of adverse events during 1 year of follow-up. Results: Eight of the 11 DP-treated patients and all 9 PP-treated patients achieved remission. Mean time to remission was 173 days with DP and 176 days with PP. The mean duration of remission within the first year was 151 days for DP and 141 days for PP. Mean cumulative prednisolone dose was 5300 mg for DP and 4882 mg for PP. Weight gain (>5{\%} of baseline) occurred in 8 DP-treated patients compared with 1 PP-treated patient (P",
author = "Mentink, {Leon F.} and Mackenzie, {Maria W.} and T{\'o}th, {G{\'a}bor G.} and Marianne Laseur and Lambert, {Frank P G} and Veeger, {Nic J G M} and Giuseppe Cianchini and Pavlović, {Miloš D.} and Jonkman, {Marcel F.}",
year = "2006",
month = "5",
doi = "10.1001/archderm.142.5.570",
language = "English",
volume = "142",
pages = "570--576",
journal = "Archives of Dermatology",
issn = "0003-987X",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris

T2 - PEMPULS trial

AU - Mentink, Leon F.

AU - Mackenzie, Maria W.

AU - Tóth, Gábor G.

AU - Laseur, Marianne

AU - Lambert, Frank P G

AU - Veeger, Nic J G M

AU - Cianchini, Giuseppe

AU - Pavlović, Miloš D.

AU - Jonkman, Marcel F.

PY - 2006/5

Y1 - 2006/5

N2 - Objective: To determine the therapeutic effect of adjuvant dexamethasone pulse therapy when given in addition to conventional treatment of pemphigus vulgaris. Design: A randomized, placebo-controlled trial. Setting: International European, multicenter outpatient and inpatient study. Patients: Of the 20 enrolled patients, 11 were randomized to the dexamethasone pulse (DP) group and 9 to the placebo pulse (PP) group. Interventions: Oral dexamethasone in 300-mg pulses or PPs 3 days per month. During the intervention, the DP and PP groups received conventional treatment with prednisolone, 80 mg/d, which was tapered across 19 weeks, and azathioprine sodium, 3 mg/kg per day, until the end of the study. Monthly pulses were continued until prednisolone treatment was tapered to 0 mg. Main Outcome Measures: Number of patients in remission, time to and duration of remission, cumulative prednisolone dose, and occurrence of adverse events during 1 year of follow-up. Results: Eight of the 11 DP-treated patients and all 9 PP-treated patients achieved remission. Mean time to remission was 173 days with DP and 176 days with PP. The mean duration of remission within the first year was 151 days for DP and 141 days for PP. Mean cumulative prednisolone dose was 5300 mg for DP and 4882 mg for PP. Weight gain (>5% of baseline) occurred in 8 DP-treated patients compared with 1 PP-treated patient (P

AB - Objective: To determine the therapeutic effect of adjuvant dexamethasone pulse therapy when given in addition to conventional treatment of pemphigus vulgaris. Design: A randomized, placebo-controlled trial. Setting: International European, multicenter outpatient and inpatient study. Patients: Of the 20 enrolled patients, 11 were randomized to the dexamethasone pulse (DP) group and 9 to the placebo pulse (PP) group. Interventions: Oral dexamethasone in 300-mg pulses or PPs 3 days per month. During the intervention, the DP and PP groups received conventional treatment with prednisolone, 80 mg/d, which was tapered across 19 weeks, and azathioprine sodium, 3 mg/kg per day, until the end of the study. Monthly pulses were continued until prednisolone treatment was tapered to 0 mg. Main Outcome Measures: Number of patients in remission, time to and duration of remission, cumulative prednisolone dose, and occurrence of adverse events during 1 year of follow-up. Results: Eight of the 11 DP-treated patients and all 9 PP-treated patients achieved remission. Mean time to remission was 173 days with DP and 176 days with PP. The mean duration of remission within the first year was 151 days for DP and 141 days for PP. Mean cumulative prednisolone dose was 5300 mg for DP and 4882 mg for PP. Weight gain (>5% of baseline) occurred in 8 DP-treated patients compared with 1 PP-treated patient (P

UR - http://www.scopus.com/inward/record.url?scp=33646559224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646559224&partnerID=8YFLogxK

U2 - 10.1001/archderm.142.5.570

DO - 10.1001/archderm.142.5.570

M3 - Article

VL - 142

SP - 570

EP - 576

JO - Archives of Dermatology

JF - Archives of Dermatology

SN - 0003-987X

IS - 5

ER -